ES2566033T3 - Parvovirus recombinante atenuado - Google Patents

Parvovirus recombinante atenuado Download PDF

Info

Publication number
ES2566033T3
ES2566033T3 ES11706253.9T ES11706253T ES2566033T3 ES 2566033 T3 ES2566033 T3 ES 2566033T3 ES 11706253 T ES11706253 T ES 11706253T ES 2566033 T3 ES2566033 T3 ES 2566033T3
Authority
ES
Spain
Prior art keywords
attenuated recombinant
recombinant parvovirus
attenuated
parvovirus
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11706253.9T
Other languages
English (en)
Spanish (es)
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2566033T3 publication Critical patent/ES2566033T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/23Parvoviridae, e.g. feline panleukopenia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14361Methods of inactivation or attenuation
    • C12N2750/14362Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES11706253.9T 2010-03-05 2011-03-03 Parvovirus recombinante atenuado Active ES2566033T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31103210P 2010-03-05 2010-03-05
US311032P 2010-03-05
EP10155646 2010-03-05
EP10155646 2010-03-05
PCT/EP2011/053164 WO2011107534A1 (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Publications (1)

Publication Number Publication Date
ES2566033T3 true ES2566033T3 (es) 2016-04-08

Family

ID=42562704

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11706253.9T Active ES2566033T3 (es) 2010-03-05 2011-03-03 Parvovirus recombinante atenuado

Country Status (10)

Country Link
US (1) US9234182B2 (enExample)
EP (1) EP2542260B1 (enExample)
JP (3) JP6200155B2 (enExample)
CN (1) CN102791288B (enExample)
AU (1) AU2011222910B2 (enExample)
CA (1) CA2790653C (enExample)
DK (1) DK2542260T3 (enExample)
ES (1) ES2566033T3 (enExample)
RU (1) RU2527157C2 (enExample)
WO (1) WO2011107534A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791288B (zh) * 2010-03-05 2015-02-18 英特维特国际股份有限公司 重组的减毒细小病毒
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140234354A1 (en) * 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
ES2771850T3 (es) 2014-04-17 2020-07-07 Intervet Int Bv Parvovirus porcino
PT3534945T (pt) 2016-11-03 2025-06-30 Boehringer Ingelheim Vetmedica Gmbh Vacina contra o parvovírus suíno
MX380632B (es) 2016-11-03 2025-03-12 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio y reproductivo porcino y métodos de producción de esta.
US20230405110A1 (en) 2020-11-04 2023-12-21 Intervet, Inc. Canine Parvovirus
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
CA2348382C (en) * 1998-11-10 2013-09-17 The University Of North Carolina At Chapel Hill Chimeric parvovirus vectors and methods of making and administering the same
CN101563096A (zh) * 2005-07-28 2009-10-21 辉瑞产品公司 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法
NZ614571A (en) * 2007-06-14 2014-12-24 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
CN102791288B (zh) * 2010-03-05 2015-02-18 英特维特国际股份有限公司 重组的减毒细小病毒

Also Published As

Publication number Publication date
DK2542260T3 (en) 2016-06-06
AU2011222910A1 (en) 2012-09-27
CN102791288B (zh) 2015-02-18
BR112012021650A2 (pt) 2017-02-21
CN102791288A (zh) 2012-11-21
WO2011107534A1 (en) 2011-09-09
CA2790653C (en) 2019-02-19
JP2018134088A (ja) 2018-08-30
EP2542260B1 (en) 2016-03-02
US20120328652A1 (en) 2012-12-27
JP2013520977A (ja) 2013-06-10
RU2012142309A (ru) 2014-04-10
RU2527157C2 (ru) 2014-08-27
AU2011222910B2 (en) 2014-09-18
EP2542260A1 (en) 2013-01-09
US9234182B2 (en) 2016-01-12
JP2016047053A (ja) 2016-04-07
JP6346143B2 (ja) 2018-06-20
JP6200155B2 (ja) 2017-09-20
CA2790653A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
ES2566033T3 (es) Parvovirus recombinante atenuado
ES2569365T3 (es) Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
ES2683695T3 (es) Repeticiones terminales invertidas restrictivas para vectores virales
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
CL2012002969A1 (es) Vector viral adenoasociado recombinante (raav) que comprende promotor de rodopsina quinasa humana especifica del fotorreceptor, o promotor de beta-actina de pollo cmv quimerico truncado ubicuo unido a al menos un adn que codifica una guanilato ciclasa; virion o particula viral infecciosa que comprende el vector; celula huesped; composicion que comprende el vector.
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
ECSP15011603A (es) Subunidades de vacunas de inmersión para peces
EP3795581A3 (en) New avv capsid proteins for nucleic acid transfer
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
MX385620B (es) Transferencia de genes al sistema nervioso central mediada por virus adeno-asociados.
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079972A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
CY1118250T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
JP2013510581A5 (enExample)
MX2016010649A (es) Vector de virus adeno-asociado.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
EA201001045A1 (ru) Модифицированный вирус гриппа
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
BR112012003837B8 (pt) Vacina de paramyxovírus aviária recombinante e método para fazer e usar a mesma
MY173789A (en) North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
PH12014502534A1 (en) Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning